Skip to content
The Intraday
Pulse

Briefings

Morning BriefOvernight tape and the setup for the openMid-Morning UpdateWhat changed after the opening bell

Markets

Market DashboardTape, movers, watchlist, and cross-asset contextPre-Market SheetOvernight setup, futures, and early moversGlobal SessionsInternational clocks and index performanceInsider ActivityLatest reported executive transactions

STAA Research

Price ChartTechnical charting and drawing workspaceFundamentals ChartCompare financial metrics across timeCompany OverviewA visual snapshot of company performanceFinancial StatementsPrice, filings, key statistics, and news

Newsletter

Morning Production ReportRanked stories, charts, and newsletter readiness

Financial Statements

Explore

Markets, briefings, and company research

STAA
Pulse

Briefings

MorningMid-Morning

Markets

DashboardPre-MarketGlobalInsiders

STAA Research

ChartFundamentalsOverviewFinancials

Newsletter

Morning Report

Newsletter operations and account tools are available from your profile menu after sign-in.

STAAR Surgical Company

STAA
$23.12
+$0.26 (1.14%)+1.14%
Closed
Loading chart...
IndexN/A
Market Cap1.15B
Enterprise Value1.06B
Income$-0.05B
Sales$0.04B
EmployeesN/A
P/E40.56
P/S4.89
P/B3.40
P/C-29.21
EV/EBITDA-14.35
EV/SalesN/A
EPS (ttm)0.57
EarningsN/A
Gross Margin76.19%
Oper. Margin-19.19%
Profit Margin-33.60%
Volume0.71M
Shs Outstand0.05B
Change1.14%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
Income Statement by fiscal year, newest to oldest
MetricFY 2024FY 2023FY 2022FY 2021FY 2020FY 2018FY 2017FY 2016
Revenue$313.90M$322.42M$284.39M$230.47M$150.19M$123.95M$90.61M$82.43M
Cost of Revenue$74.32M$69.76M$61.01M$51.84M$38.23M$32.44M$26.33M$24.06M
Gross Profit$239.58M$252.65M$223.38M$178.64M$111.95M$91.51M$64.28M$58.37M
Gross Margin76.32%78.36%78.55%77.51%74.54%73.83%70.94%70.81%
Operating Expenses$252.19M$224.55M$179.58M$145.30M$100.10M$84.92M$67.91M$71.02M
Operating Income$-12.61M$28.10M$43.80M$33.34M$11.85M$6.59M$-3.63M$-12.65M
Operating Margin-4.02%8.71%15.40%14.47%7.89%5.32%-4.01%-15.35%
Net Income$-20.21M$21.35M$39.66M$27.51M$14.05M$4.97M$-2.14M$-12.13M
Net Margin-6.44%6.62%13.95%11.94%9.35%4.01%-2.36%-14.71%
EPS (Basic)$-0.41$0.44$0.83$0.52$0.32$0.11$-0.05$-0.30
EBITDAN/AN/AN/AN/AN/AN/AN/AN/A
Stock Option Compensation ExpenseN/AN/AN/AN/AN/AN/AN/AN/A
Price To Earnings RatioN/AN/AN/AN/AN/AN/AN/AN/A
Price To Sales RatioN/AN/AN/AN/AN/AN/AN/AN/A
Shares OutstandingN/AN/AN/AN/AN/AN/AN/AN/A
Market CapitalizationN/AN/AN/AN/AN/AN/AN/AN/A
Balance Sheet by fiscal year, newest to oldest
MetricFY 2024FY 2023FY 2022FY 2021FY 2020FY 2018FY 2017FY 2016
Cash & Short Term InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Short Term ReceivablesN/AN/AN/AN/AN/AN/AN/AN/A
InventoriesN/AN/AN/AN/AN/AN/AN/AN/A
Other Current AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Total Current AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Net Property, Plant & EquipmentN/AN/AN/AN/AN/AN/AN/AN/A
Total Investments and AdvancesN/AN/AN/AN/AN/AN/AN/AN/A
Long-Term Note ReceivableN/AN/AN/AN/AN/AN/AN/AN/A
Intangible AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Deferred Tax AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Other AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Total Assets$509.52M$488.69M$418.82M$345.78M$207.52M$167.34M$67.93M$65.44M
Short Term Debt Incl. Current Port. of LT DebtN/AN/AN/AN/AN/AN/AN/AN/A
Accounts PayableN/AN/AN/AN/AN/AN/AN/AN/A
Income Tax PayableN/AN/AN/AN/AN/AN/AN/AN/A
Other Current LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Total Current LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Provision for Risks ChargesN/AN/AN/AN/AN/AN/AN/AN/A
Deferred Tax LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Other LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Total Liabilities$112.19M$102.74M$82.71M$87.22M$47.64M$34.91M$25.00M$27.54M
Non-Equity ReservesN/AN/AN/AN/AN/AN/AN/AN/A
Preferred Stock - Carrying ValueN/AN/AN/AN/AN/AN/AN/AN/A
Common EquityN/AN/AN/AN/AN/AN/AN/AN/A
Total Shareholders Equity$397.33M$385.95M$336.11M$258.56M$159.88M$132.43M$42.94M$37.91M
Accumulated Minority InterestN/AN/AN/AN/AN/AN/AN/AN/A
Total Equity$397.33M$385.95M$336.11M$258.56M$159.88M$132.43M$42.94M$37.91M
Total Liabilities & Stockholders Equity$509.52M$488.69M$418.82M$345.78M$207.52M$167.34M$67.93M$65.44M
Book Value Per ShareN/AN/AN/AN/AN/AN/AN/AN/A
Tangible Book Value Per ShareN/AN/AN/AN/AN/AN/AN/AN/A
Full-Time EmployeesN/AN/AN/AN/AN/AN/AN/AN/A
Price to Book RatioN/AN/AN/AN/AN/AN/AN/AN/A
Return on AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Return on EquityN/AN/AN/AN/AN/AN/AN/AN/A
Return on Invested CapitalN/AN/AN/AN/AN/AN/AN/AN/A
Quick RatioN/AN/AN/AN/AN/AN/AN/AN/A
Current RatioN/AN/AN/AN/AN/AN/AN/AN/A
Cash Flow by fiscal year, newest to oldest
MetricFY 2024FY 2023FY 2022FY 2021FY 2020FY 2018FY 2017FY 2016
Net Income$-20.21M$21.35M$39.66M$27.51M$14.05M$4.97M$-2.14M$-12.13M
DepreciationN/AN/AN/AN/AN/AN/AN/AN/A
Other Funds (Non Cash)N/AN/AN/AN/AN/AN/AN/AN/A
Funds from OperationsN/AN/AN/AN/AN/AN/AN/AN/A
Extraordinary ItemN/AN/AN/AN/AN/AN/AN/AN/A
Changes in Working CapitalN/AN/AN/AN/AN/AN/AN/AN/A
Income Taxes PayableN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Operating Activities$15.72M$14.59M$35.72M$43.96M$25.80M$12.77M$2.85M$1.05M
Capital ExpendituresN/AN/AN/AN/AN/AN/AN/AN/A
Net Assets From AcquisitionsN/AN/AN/AN/AN/AN/AN/AN/A
Sale of Fixed Assets and BusinessesN/AN/AN/AN/AN/AN/AN/AN/A
Purchase or Sale of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Purchase of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Sale Or Maturity of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Other UsesN/AN/AN/AN/AN/AN/AN/AN/A
Other SourcesN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Investing ActivitiesN/AN/AN/AN/AN/AN/AN/AN/A
Cash Dividends PaidN/AN/AN/AN/AN/AN/AN/AN/A
Change in Capital StockN/AN/AN/AN/AN/AN/AN/AN/A
Repurchase of Common Pref StockN/AN/AN/AN/AN/AN/AN/AN/A
Sale of Common Pref StockN/AN/AN/AN/AN/AN/AN/AN/A
Proceeds from Stock OptionsN/AN/AN/AN/AN/AN/AN/AN/A
Issuance or Reduction of Debt, NetN/AN/AN/AN/AN/AN/AN/AN/A
Change in Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Issuance of Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Reduction of Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Net Financing Active Other Cash FlowN/AN/AN/AN/AN/AN/AN/AN/A
Other Financing Activities UsesN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Financing ActivitiesN/AN/AN/AN/AN/AN/AN/AN/A
Exchange Rate EffectN/AN/AN/AN/AN/AN/AN/AN/A
Net Change in CashN/AN/AN/AN/AN/AN/AN/AN/A
Free Cash FlowN/AN/AN/AN/AN/AN/AN/AN/A
Preferred Dividends (Cash Flow)N/AN/AN/AN/AN/AN/AN/AN/A
Price to Free Cash FlowN/AN/AN/AN/AN/AN/AN/AN/A

Company coverage

Latest news

20 stories
Aug 5 · 1:01PMStaar Surgical (STAA) Upgraded to Strong Buy: What Does It Mean for the Stock?zacks.com ↗Aug 4 · 4:05PMSTAAR Surgical Appoints Warren Foust as President and Chief Executive Officerbusinesswire.com ↗Jul 17 · 5:31PMSTAAR Surgical's Punishment For Opacity Is Justseekingalpha.com ↗Jul 17 · 8:41AMCaution Lingers for STAAR Surgical Amid Middle East Geopolitical Tensionsbenzinga.com ↗Jul 16 · 4:01PMSTAAR Surgical Announces Preliminary Net Sales for Second Quarter 2026businesswire.com ↗Jun 1 · 12:14PMHedge Fund Broadwood Capital Added Over 1 Million Shares of STAAR Surgical to Its Position. Here's What That Means for Investors.fool.com ↗May 28 · 8:40PMStaar Surgical Co (STAA) Stock Down 7.3% -- Now Undervalued? GF Score: 81/100gurufocus.com ↗May 28 · 1:20AMSTAAR Surgical Company (STAA) Discusses Differentiation of EVO ICL Technology and Market Trends in Refractive Surgery Transcriptseekingalpha.com ↗
Show 12 more stories↓
May 21 · 4:01PMSTAAR Surgical Announces Participation in Upcoming Investor Conferencesbusinesswire.com ↗May 16 · 10:10AMSTAAR Surgical Q1 2026: Early Signs Of A Durable Turnaroundseekingalpha.com ↗May 14 · 12:06PMWhy It's Time To Take Profits In This Top-Rated Medical Stockinvestors.com ↗May 14 · 1:20AMSTAAR Surgical Company (STAA) Q1 2026 Earnings Call Transcriptseekingalpha.com ↗May 14 · 12:14AMSTAAR Surgical Q1 Earnings Call Highlightsmarketbeat.com ↗May 13 · 6:30PMCompared to Estimates, Staar Surgical (STAA) Q1 Earnings: A Look at Key Metricszacks.com ↗May 13 · 6:15PMStaar Surgical (STAA) Tops Q1 Earnings and Revenue Estimateszacks.com ↗May 4 · 4:01PMSTAAR Surgical to Host First Quarter 2026 Earnings Results Call and Webcast on May 13, 2026businesswire.com ↗May 1 · 6:18PMA Look at Staar Surgical Co (STAA) After 3.1% Gain -- GF Value $29.11 vs Price $27.19gurufocus.com ↗Apr 30 · 11:06AMMcKesson (MCK) Earnings Expected to Grow: What to Know Ahead of Next Week's Releasezacks.com ↗Apr 29 · 11:02AMStaar Surgical (STAA) Earnings Expected to Grow: What to Know Ahead of Q1 Releasezacks.com ↗Apr 9 · 12:32PMSTAAR Surgical Shares Jump 25% on Blowout $90M Sales Outlookgurufocus.com ↗

Insider Trading

View All
Insider
Type
Shares
Price
Value
Date
ANDREWS DEBORAH J
Option
20.8K
—
—
Jul 31, 26
Foust Warren
Option
20.8K
—
—
Jul 31, 26
Wang Christopher Min Fang
Award
11.1K
$29.12
$325K
Jun 18, 26
Jiang Wei
Option
10.7K
—
—
Jun 18, 26
SILVERMAN LOU
Option
10.7K
—
—
Jun 18, 26

Company

CEO: Deborah J. AndrewsEmployees: 957www.staar.com
About the company↓

STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.

Discover more

You may be interested in
AMD

Advanced Micro Devices

$489.28

↑ 1.50%
ABX

Abacus Global Management Inc

$10.40

↓ 1.52%
META

Meta Platforms Inc

$589.90

↑ 0.19%
V

Visa Inc

$370.47

↑ 0.52%
DIS

Walt Disney Co

$104.67

↑ 2.86%
CRM

Salesforce Inc

$186.77

↓ 3.22%
ADBE

Adobe Inc

$260.24

↑ 0.35%
TSLA

Tesla Inc

$319.53

↓ 0.63%
NVDA

NVIDIA Corp

$218.99

↓ 0.10%
IBM

IBM Corp

$233.43

↓ 1.06%
JPM

JPMorgan Chase & Co

$356.30

↓ 0.82%
BAC

Bank of America Corp

$63.00

↓ 0.40%
The Intraday

© 2026 The Intraday. All rights reserved.

Market data may be delayedFor informational purposes onlyFMP · Massive · SEC